MediWound Ltd (NASDAQ: MDWD ) announced results from its Phase 2 pharmacology study of EscharEx for the debridement of lower leg ulcers.
70% of patients achieved complete debridement during treatment within up to 8 applications. On average, complete debridement was achieved after 3.9 applications of EscharEx.
Additionally, ... Full story available on Benzinga.com